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A lthough guidelines for many chronic diseases recommend targets to pursue as an important aspect of their management, there is considerable disagreements 
between organizations concerning which targets should be chosen, as well as what 
would be the optimum value for a specific target (1-6). These disagreements have 
become more pronounced recently for diabetes and dyslipidemias (1-4). In 2012 the 
American Diabetes Association and the European Association for the Study of Dia-
betes published a position statement on the management of type 2 diabetes in which 
remarkable changes were observed in relation to the previous recommendations (1). 
This was mainly due to the advent of new therapies, but also because new knowledge 
has emerged on the long-term adverse effects of drug therapy, especially the risk of hy-
poglycemia with more intensive control and consequently an increased cardiovascular 
risk. This was followed by the announcement of the 2013 diabetes algorithm propo-
sed by the American Association of Clinical Endocrinologists, which introduced more 
rigorous targets for blood glucose control for the newly-diagnosed type 2 patient and 
more aggressive therapies and targets for the pre-diabetes states (2). At the end of 
2013, another notable change occurred with the release of the American College of 
Cardiology/American Heart Association hypercholesterolemia guidelines (3), more 
evidence-based than the previous NCEP (National Cholesterol Education Program) 
guidelines, using more robust data to calculate absolute risk based on multiple pros-
pective cohort studies, calibrating the calculations on intervention studies on primary 
prevention of major cardiovascular events with statins and considering the long-term 
side effects and drug interaction, especially in the more vulnerable elderly patient. 
New targets were proposed based on percentage changes in LDL-C as a target for 
statin therapy, and not simply a low or very low absolute value for LDL-C as some 
continue to advocate (4). Guidelines for hypertriglyceridemia and hypertension have 
also resulted in disagreement on when to start drug therapy or which targets should 
be pursued during treatment, especially in populations such as individuals with type 2 
diabetes and in the elderly (5-7).
Is it time to consider the same approach to osteoporosis treatment? As with other 
chronic conditions, the field of osteoporosis has been growing fast and new noninva-
sive methods for the evaluation of bone turnover and strength are now available. In 
this issue of the journal many aspects of these new tools will be discussed.
Biochemical markers of bone remodeling are now widely available and a review of 
recent data suggests that they can be used as a target related to the effects of osteopo-
rosis drugs and the prediction of a decrease in fracture risk (8). Particularly worthy of 
mention in this connection are the reduction on serum beta-CTX (C-terminal telo-
peptide) during anti-resorptive therapy and the rise in serum P1NP (Serum collagen 
type 1 N-terminal propeptide) and osteocalcin during anabolic therapy with teripa-
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ratide (8,9). Even strontium ranelate, which leads to 
slight changes in bone markers in postmenopausal wo-
men with osteoporosis who had never taken any bone 
medication, can induce significant changes in bone 
mar kers in women previously treated with bisphospho-
nates (9,10) and these changes may be associated with 
an improvement in bone mineral density (BMD). 
Much more controversy exists in relation to target 
bone mineral density values during osteoporosis treat-
ment. Some studies suggest (11) that even patients with 
a decline in BMD may still benefit from oral bisphos-
phonate therapy. These patients may exhibit a reduced 
risk for fracture than those on a placebo, despite having 
a suboptimal BMD response, although the risk reduc-
tion is more pronounced in those patients who have 
experienced an unequivocal increase in BMD. It may 
therefore be difficult to tell a patient on bisphospho-
nate treatment who has experienced a decline in BMD 
over time that she has really lost her protection against 
osteoporotic fractures.
As in other chronic diseases, the new knowledge 
on the adverse effects of long-term therapy has also 
been evaluated for osteoporosis, and this is particularly 
true for atypical femoral fractures, which may exhibit 
a sharp increase in incidence with the long-term use 
of bisphosphonates (12,13). Although rare, individu-
ally these fractures may have a great impact on health, 
owing to the patient’s considerable disability (13). As 
yet insufficient data is available for denosumab, which 
can also cause atypical femoral fractures and needs to be 
used continuously as it has no residual effects on bone 
after therapy has been discontinued (14).
In view of the above, another new target proposed in 
the treatment of osteoporosis is to limit the duration of 
bisphosphonate use to 3-5 years (15) and consider a drug 
holiday for those compounds which have residual effects 
on bone, such as alendronate and zoledronic acid, or even 
decrease the dose of alendronate for the high-risk patient 
in whom more prolonged therapy is preferred (16).
Hopefully, other methods developed to evaluate 
bone quality, such as trabecular bone score (TBS) on 
vertebral BMD images and peripheral high-resolution 
quantitative computed tomography (HR-pQCT), will 
be widely available for clinical use in the near future 
(17,18). This will allow more precise targets to be re-
commended for osteoporosis therapy.  
Disclosure: Dr. Bandeira receives consultant fees from Sanofi.
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